

TORRENT PHARMACEUTICALS LIMITED

Registered Office: Torrent House, Off Ashram Road, Ahmedabad - 380 009, Ph.: + 91 79 26599000 Fax: + 91 79 26582100 CIN: L24230GJ1972PLC002126; Website:www.torrentpharma.com; Email: investorservices@torrentpharma.com

| | [Rs. in Crores except per share data | | | | |
|--|--------------------------------------|----------------|-------------|--------------|--|
| Statement of Consolidated Resul | ts for the Quart | | -2017 | r rear enueu | |
| | Quarter ended | | | (Audited) | |
| Particulars | 30-Jun-2017 | 31-Mar-2017 | 30-Jun-2016 | 31-Mar-2017 | |
| | (Unaudited) | (Audited) | (Unaudited) | (Audited) | |
| | | (Refer note 5) | | | |
| Revenue | | | | | |
| Net Sales (including excise duty) | 1348 | 1381 | 1513 | 5713 | |
| Other operating income | 26 | 53 | 38 | 144 | |
| Revenue from operations (net) | 1374 | 1434 | 1551 | 5857 | |
| Other income | 105 | 104 | 26 | . 223 | |
| Total Revenue | 1479 | 1538 | 1577 | 6080 | |
| Expenses | | | | | |
| Cost of materials consumed | 250 | 230 | 343 | 1180 | |
| Purchases of stock-in-trade | 200 | 185 | 182 | 751 | |
| Changes in inventories of finished goods, work-in- | | | | | |
| progress and stock-in-trade | (49) | 75 | (88) | (140 | |
| Employee benefits expense | 263 | 249 | 252 | 993 | |
| Finance costs | 56 | 58 | 49 | 206 | |
| Depreciation and amortisation expense | 80 | 97 | 68 | 307 | |
| Other expenses | 413 | 400 | 425 | 1695 | |
| Total expenses | 1213 | 1294 | 1231 | 4992 | |
| Profit from ordinary activities before tax | 266 | | | | |
| • | 200 | 244 | 346 | 1088 | |
| Tax expense | | } | | | |
| Current Tax | 41 | 71 | 126 | 294 | |
| Deferred Tax | 37 | (41) | (72) | (148 | |
| Short / (excess) provision of earlier periods | 0 | 8 | 0 | 8 | |
| Total tax expense | 78 | 38 | 54 | 154 | |
| Net Profit for the period | 188 | 206 | 292 | 934 | |
| Attributable to : | | | | • | |
| - Owners of the company | 188 | 206 | 292 | 934 | |
| - Non controlling Interest * | 0 | 0 | 0 | | |
| Other Comprehensive Income | | | | | |
| Items that will not be reclassified to profit or loss | (3) | (2) | (3) | (12 | |
| Income tax relating to items that will not be reclassified | | | | | |
| to profit or loss | 1 | 0 | 1 | 4 | |
| Items that will be reclassified to profit or loss | (75) | 111 | (19) | 189 | |
| Income tax relating to items that will be reclassified to | | | | | |
| profit or loss | 23 | (30) | 2 | (55 | |
| Total other comprehensive income | · (54) | 79 | (19) | 126 | |
| Total Comprehensive Income | 134 | 285 | 273 | 1060 | |
| Attributable to : | 134 | 265 | 2/3 | 1000 | |
| - Owners of the company | 134 | 285 | 273 | 1060 | |
| - Non controlling Interest * | 0 | 283 | 2/3 | _ | |
| | | | | (| |
| Paid-up equity share capital (Face value of Rs. 5 each) | 85 | 85 | 85 | 85 | |
| Other Equity excluding Revaluation Reserves | | | | 4266 | |
| Earnings per share (of Rs. 5/- each) (not annualised for | | | | | |
| the quarter): | | | | | |
| Basic LE LIASKINS & | 11.08 | 12.17 | 17.28 | 55.17 | |
| Diluted | 11.08 | 12.17 | 17.28 | 55.17 | |

^{*} Less than Rs. 1 crore

Notes:

- The above results were reviewed by the Audit and Risk Management Committee and approved by the Board of Directors of the Parent Company, in their respective meetings held on 31-July-2017. The auditor have carried out review of the above said results. There is no qualification in the Auditors report on this statement of financial results.
- 2 The consolidated financial results include the financial results of Sixteen wholly owned subsidiaries and one partnership firm with that of the Company.
- 3 The Group operates in a single segment i.e Generic Formulation Business.
- 4 (a) The listed Non Convertible Debentures of the Parent Company aggregating to Rs. 990 crores as on 30-Jun-2017 (previous year ended Rs. 490 crores) are secured by way of first pari passu charge created through mortgage on certain specified immovable & movable assets and hypothecation of identified trademarks of the Parent Company and the asset cover thereof exceeds hundred percent of the principal amount of the said debentures.
 - (b) The listed Non Convertible Debentures of the Parent Company aggregating to Rs. 500 crores as on 30-Jun-2017 (previous year ended Rs. 1000 crores) to be secured by way of first pari passu charge on certain specified immovable & movable assets and identified trademarks of the Parent Company.
- The figures for the quarter ended 31-Mar-2017 is the balancing figures between audited figures in respect of the full financial years and the published unaudited year to date figures upto the end of the third quarter of financial year, which were subject to limited review.
- Results for the year ended 31st March, 2017 and quarter ended 30th June, 2016 include exceptional revenues and profits primarily on account of launch of a new product in the USA which had limited competition.
- 7 The figures for the corrosponding previous period have been restated/regrouped wherever necessary, to make them comparable.

For TORRENT PHARMACEUTICALS LIMITED

SAMIR MENT

Executive Chairma

Date : 31-July-2017

Place: Ahmedabad, Gujarat

